26. Global Financing Facility. (n.d.). Global Financing Facility. Retrieved November 12, 2025, from https://www.globalfinancingfacility.org/ 27. Zaigham, M., et al. (2025, September). Investing in women’s health: Blended finance for cancer care. The Lancet Obstetrics, Gynaecology, & Women’s Health, 1(1), E15. https://www.thelancet.com/journals/lanogw/article/PIIS3050- 5038(25)00016-0/fulltext 28. Bastian-Pétrel, K., et al. (2024). Sex and gender bias in chronic coronary syndromes research: Analysis of studies used to inform the 2019 European Society of Cardiology guidelines. The Lancet Regional Health – Europe, 45, 101041. https://doi.org/10.1016/j.lanepe.2024.101041 29. Hologic. (n.d.). Experts sound alarm on gender gaps in medical reimbursement rates and their impact on women’s health. Retrieved November 12, 2025, from https://www.hologic.com/about/newsroom/experts-sound-alarm-gender-gaps- medical-reimbursement-rates-and-their-impact-womens 30. McKiever, M., Frey, H., & Costantine, M. M. (2020). Challenges in conducting clinical research studies in pregnant women. Journal of Pharmacokinetics and Pharmacodynamics, 47(4), 287–293. https://doi.org/10.1007/s10928-020- 09687-z 31. Agarwal, S. K., et al. (2019). Clinical diagnosis of endometriosis: A call to action. American Journal of Obstetrics and Gynecology, 220(4), 354.e1–354.e12. https://doi.org/10.1016/j.ajog.2018.12.039 32. Stott, T., et al. (2025). PCR45 Rethinking women’s health: Unpacking the 2024 women’s health research roadmap with a landscape review of clinical outcome assessments (COA), health agency recommendations and drug label claims with COA related to women’s health. Value in Health, 28(6), S318. https://doi.org/10.1016/j.jval.2025.04.1367 33. Silicon Valley Bank. (2025). Innovation in women’s health. https://www.svb.com/trends-insights/reports/womens-health- report/ 34. Gibson, L. (2025, April 24). Federal funding cuts impact the Women’s Health Initiative (WHI). Harvard Magazine. https://www.harvardmagazine.com/2025/04/harvard-joann-mason-brigham-womens-hospital-funding-cuts 35. MM+M – Medical Marketing and Media. (2025, September 3). How federal funding cuts impact women’s health innovation. https://www.mmm-online.com/features/how-federal-funding-cuts-impact-womens-health-innovation/ 36. Royal College of Obstetricians and Gynaecologists. (2025, January 28). RCOG responds to reports that central support for women’s health hubs will end. https://www.rcog.org.uk/news/rcog-responds-to-reports-that-central-support-for- women-s-health-hubs-will-end/ 37. Climate Policy Initiative. (2024, October). Global landscape of climate finance 2024. https://www.climatepolicyinitiative. org/publication/global-landscape-of-climate-finance-2024/ 38. Eskew, A. M., & Jungheim, E. S. (2017). A history of developments to improve in vitro fertilization. Missouri Medicine, 114(3), 156–159. https://pubmed.ncbi.nlm.nih.gov/30228571/ 39. eClinicalMedicine. (2023, November). The current status of IVF: Are we putting the needs of the individual first? eClinicalMedicine, 65, 102343. https://doi.org/10.1016/j.eclinm.2023.102343 40. Boston Consulting Group research and analysis, which included the following sources: Latin American Registry; European Society of Human Reproduction and Embryology; Canadian Assisted Reproductive Technologies Register; Centers for Disease Control and Prevention, Society for Assisted Reproductive Technology; International Journal for Equity in Health; Fertility Europe; United Arab Emirates Government Portal; National Institutes of Health; University of New South Wales; Colliers; Singapore Ministry of Health; Market participant interviews. 41. 9fin. (2025, June 9). Reproductive services are fertile ground for private credit opportunities. https://9fin.com/insights/ fertile-ground-pc 42. IVF-Worldwide. (n.d.). The history of IVF history. Retrieved November 12, 2025, from https://ivf-worldwide.com/ivf- history.html 43. Payers refers to entities responsible for financing or reimbursing healthcare services. This includes government health programmes (e.g. national health systems or social insurance), private health insurance companies and employer- sponsored health plans. 44. Eskew, A. M., & Jungheim, E. S. (2017). A history of developments to improve in vitro fertilization. Missouri Medicine, 114(3), 156–159. https://pubmed.ncbi.nlm.nih.gov/30228571/ 45. American Society for Reproductive Medicine. (2023). Planned oocyte cryopreservation to preserve future reproductive potential: An Ethics Committee opinion. https://www.asrm.org/practice-guidance/ethics-opinions/planned-oocyte- cryopreservation/ 46. Borsa, A., & Bruch, J. D. (2022). Prevalence and performance of private equity–affiliated fertility practices in the United States. Fertility and Sterility, 117(1), 124–130. https://www.fertstert.org/article/S0015-0282%2821%2901976-2/fulltext 47. Thompson, C. (2016). IVF global histories, USA: Between Rock and a marketplace. Reproductive Biomedicine & Society Online, 2, 128–135. https://www.sciencedirect.com/science/article/pii/S2405661816300235 48. McMullin, C. (2024, August 22). Organizations adding more fertility and adoption support. Word on Benefits. https://blog. ifebp.org/organizations-adding-more-fertility-and-adoption-support/ 49. Progyny. (2019, October 24). Progyny, Inc. announces pricing of initial public offering. https://investors.progyny.com/ news-releases/news-release-details/progyny-inc-announces-pricing-initial-public-offering Women’s Health Investment Outlook 43

Womens Health Investment Outlook 2026